Advantag of ingestion administration way is its easiness even when applied at home. But with their help necessary treatment concentration in blood cannot be always quickly achieve amoxil online transaction is carried out on anonymity and mutual profit principles, and in addition customers will be positively surprised with quality and speed of service.

Gale.cengage.co.uk

Graham & Whiteside
Australia • Brazil • Japan • Korea • Mexico • Singapore • Spain • United Kingdom • United States Major Pharmaceutical and Biotechnology Companies of the World 2009
Africa (South of the Sahara)
Malaysia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126 Angola . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Mongolia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133 Benin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Myanmar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134 Botswana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Nepal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134 Burkina Faso . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 New Zealand . . . . . . . . . . . . . . . . . . . . . . . . . . 134 Cape Verde . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 North Korea . . . . . . . . . . . . . . . . . . . . . . . . . . . 136 Ethiopia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Pakistan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136 Gabon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Papua New Guinea . . . . . . . . . . . . . . . . . . . . . 138 Ghana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 People’s Republic of China . . . . . . . . . . . . . . . 138 Ivory Coast . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Philippines . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157 Kenya . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Singapore . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 Lesotho . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 South Korea . . . . . . . . . . . . . . . . . . . . . . . . . . . 166Sri Lanka . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174 Madagascar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Taiwan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175 Malawi . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Thailand . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178 Mali . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Vietnam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180 Mauritius . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4Mozambique . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Eastern Europe and the Commonwealth of Indepen-
Niger . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 dent States
Nigeria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Armenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182 Senegal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Belarus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182 Seychelles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Bosnia and Herzegovina . . . . . . . . . . . . . . . . . 183 South Africa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Croatia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183 Swaziland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Georgia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184 Togo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Kazakhstan . . . . . . . . . . . . . . . . . . . . . . . . . . . 184 Uganda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Macedonia . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185 Zambia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Montenegro . . . . . . . . . . . . . . . . . . . . . . . . . . . 185 Zimbabwe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Russia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185 Arab World
Serbia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189Ukraine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190 Algeria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Uzbekistan . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191 Bahrain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16Egypt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Gaza and West Bank . . . . . . . . . . . . . . . . . . . . . 22 Austria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191 Iraq . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Belgium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196 Jordan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Bulgaria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203 Kuwait . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Cyprus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204 Lebanon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 Czech Republic . . . . . . . . . . . . . . . . . . . . . . . . 205 Libyan Arab Jamahiriya . . . . . . . . . . . . . . . . . . . 30 Denmark . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209 Mauritania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 Estonia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216 Morocco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Finland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217 Oman . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221 Qatar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249 Saudi Arabia . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 Greece . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 275 Sudan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 Hungary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279 Syrian Arab Republic . . . . . . . . . . . . . . . . . . . . . 42 Iceland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284 Tunisia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 Israel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285 United Arab Emirates . . . . . . . . . . . . . . . . . . . . 44 Italy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291 UAE (Abu Dhabi) . . . . . . . . . . . . . . . . . . . . . . . . 44 Latvia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 301 UAE (Dubai) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 Liechtenstein . . . . . . . . . . . . . . . . . . . . . . . . . . 302 UAE (Fujairah) . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Lithuania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302 UAE (Ras Al Khaimah) . . . . . . . . . . . . . . . . . . . . 46 Luxembourg . . . . . . . . . . . . . . . . . . . . . . . . . . 303 UAE (Sharjah) . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Malta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303 Yemen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46 Monaco . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303Netherlands . . . . . . . . . . . . . . . . . . . . . . . . . . . 304 Asia and Australasia
Norway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311 Australia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 Poland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314 Bangladesh . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 Portugal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322 Hong Kong SAR . . . . . . . . . . . . . . . . . . . . . . . . . 58 Republic of Ireland . . . . . . . . . . . . . . . . . . . . . 327 India . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Romania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331 Indonesia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94 Slovakia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333 Iran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 Slovenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334 Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 Spain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336 Sweden . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 352 Chile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 416 Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . 359 Colombia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 418 Turkey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 374 Costa Rica . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420 UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 376 Ecuador . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 421El Salvador . . . . . . . . . . . . . . . . . . . . . . . . . . . 422 Latin America
Guatemala . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422 Argentina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399 Guyana . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422 Belize . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402 Honduras . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422 Bolivia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402 Mexico . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422 Brazil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402 Nicaragua . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429 CARIBBEAN - Antigua and Barbuda . . . . . . . . 412 Panama . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429 CARIBBEAN - Aruba . . . . . . . . . . . . . . . . . . . . 412 Paraguay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429 CARIBBEAN - Bahamas . . . . . . . . . . . . . . . . . 412 Peru . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430 CARIBBEAN - Barbados . . . . . . . . . . . . . . . . . 413 Suriname . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431 CARIBBEAN - Bermuda . . . . . . . . . . . . . . . . . . 413 Uruguay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431 CARIBBEAN - Cayman Islands . . . . . . . . . . . . 413 Venezuela . . . . . . . . . . . . . . . . . . . . . . . . . . . . 432 CARIBBEAN - Dominican Republic . . . . . . . . . 413CARIBBEAN - Grenada . . . . . . . . . . . . . . . . . . 414 North America
CARIBBEAN - Jamaica . . . . . . . . . . . . . . . . . . 414 Canada . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434 CARIBBEAN - Netherlands Antilles . . . . . . . . . 415 USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 440 CARIBBEAN - Puerto Rico . . . . . . . . . . . . . . . . 415CARIBBEAN - St Lucia . . . . . . . . . . . . . . . . . . 415 CARIBBEAN - St Vincent and the Grenadines . 416 Alphabetical Index . . . . . . . . . . . . . . . . . . . . . 471 CARIBBEAN - Trinidad and Tobago . . . . . . . . . 416 Index by Country . . . . . . . . . . . . . . . . . . . . . . 495 WAKO PURE CHEMICALS INDUSTRIES . . . 00953
Rhythm, Kikuron, Kolberon, Tocks, Aoi Umi, Hakubiso, Mori TORII PHARMACEUTICAL CO LTD
VITAL-NET INC
Branch Offices: Tokyo; New York, USA; London, UK Address: 3-4-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103- Former name: Sun-S Inc
Subsidiary Companies: (100% owned unless stated): Address: 1-1 Ohtemachi, Aoba-ku, Sendai 980-8581 HOKURIKU MEDICAL SERVICE CO LTD; Taiyo Sangyo Co Ltd; Tomix Co Ltd; TOYAMA EUROPE LTD (UK); Toyama Kouei Co Ltd; TOYAMA USA Inc (USA); White Public Rela- Board of Directors: Norihiko Matsuo (President), Hiroshi Imai Board of Directors: Jun Suzuki (Chairman), Ken Suzuki (Rep- (Managing Director/Chief Pharmaceutical Marketing), Yuji Kagohashi (Director/Chief of R&D & Production), Hiroshi PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals Kanaya (Executive Deputy President/Chief of Corporate Planning & Admin), Masanori Wada (Director/QA) Senior Executives: Tadashi Kadota (Corporate Auditor), Financial Information: 2008: Consolidated Yoshiaki Otsuka (Corporate Auditor), Yoshiyuki Taniguchi Principal Shareholders: Hikoji Suzuki (6.7%); Suzuhiko Ltd (Corporate Auditor), Hideo Yamaguchi (Corporate Auditor) Sales turnover
PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals Parent Company: Japan Tobacco Inc, Japan (00864) Financial Information: Consolidated figures Sales turnover
Principal Shareholders: Japan Tobacco Inc (53.5%) TRANS GENIC INC
Address: 3-14-3 Minami-Kumamoto, Kumamoto-shi, Ku- Sales turnover
WAKAMOTO PHARMACEUTICAL CO LTD
Board of Directors: Satoru Endo (Auditor), Toshio Kajima Address: 1-5-3 Nihonbashi-Muromachi, Chuo-ku, Tokyo (Auditor), Masahiro Koreishi (President and Chief Execu- tive Officer), Yasuhiko Matsuo (Internal Auditor), Michita Satoh (Director), Jun Tanaka (Executive Director), Ken-ichi Website: www.wakamoto-pharm.co.jpBoard of Directors: Kiyoaki Makita (Chairman), Takashi Ishii PRINCIPAL ACTIVITIES: Analysis of genes and genetics infor- TOWA PHARMACEUTICAL CO LTD
Principal Banks: Shoko Chukin Bank; The Bank of Tokyo- PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals Address: 2-11 Shinbashi-cho, Kadoma 571-8580, Osaka Principal Shareholders: Kissei Pharmaceutical (9.5%); Brast- Board of Directors: Itsuro Yoshida (President) PRINCIPAL ACTIVITIES: Manufacture of drugs for respiratory Financial Information: Consolidated figures Branch Offices: Osaka; Hannan; Nagoya; Takarazuka; Sales turnover
Sales turnover
Principal Shareholders: Yoshida Jimsho (17.4%); Yoshida Kosan (11.6%); Yoshida Kikaku (8.8%); Itsuro Yoshida Date of Establishment: April 1957No of Employees: 1,125 (group)Financial Information: Consolidated figures TSUMURA & CO
WAKO PURE CHEMICALS INDUSTRIES LTD
Sales turnover
Address: 2-17-11 Akasaka, Minato-ku, Tokyo 107-8521 Address: 3-1-2 Doshomachi, Chuo-ku, Osaka 540-8605 Board of Directors: Junichi Yoshii (President) PRINCIPAL ACTIVITIES: Manufacture and sale of pharmaceu- Board of Directors: Hajime Ikezoe (President), Syunrou Kawa- ticals, quasi-pharmaceuticals and toiletries mura (Senior Managing Executive Officer), Eisuke Kimura Branch Offices: Sapporo; Sendai; Tokyo; Nagoya; Osaka; (Managing Executive Officer/GM Corporate Production/QA), Yokohama; Shizuoka; Kyoto; Kobe; Takamatsu; Tachikawa; Takeo Matsumoto (Managing Executive Officer/GM Corpo- rate Admin & Personnel), Norimichi Ueno (Senior Managing TOYAMA CHEMICAL CO LTD
Executive Officer), Yoshiharu Watabiki (Senior Managing Address: 3-2-5 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023 Senior Executives: Shigeru Fukushima (Corporate Auditor), Principal Shareholders: Japan Trustee Services Bank Eio Okayama (Corporate Auditor), Toyoji Yoshida (Corporate (12.6%); Master Trust Bank of Japan (5.7%) PRINCIPAL ACTIVITIES: Provision of laboratory chemicals, Board of Directors: Katsuhiko Nakano (Chairman), Masuji specialty chemicals and diagnostic reagents for genetic Sugata (President), Shinichiro Inushima (Director), Shozo Financial Information: Consolidated figures engineering research, tissue culture, measurement of Kakimoto (Director), Yoshiharu Murotani (Director), Akira environmental pollutants, immunological research, chro- Ohira (Director), Hideo Sanada (Director/Senior Executive matography, organic syntheses and biochemical research Officer), Yukio Yanagida (Director), Hiroichi Yoshida (Direc- Sales turnover
Subsidiary Companies: (100% owned unless stated): Wako Chemicals GmbH (Germany); Wako Chemicals USA Inc PRINCIPAL ACTIVITIES: Manufacture and sale of pharmaceu- ticals, antibiotics and industrial chemicals Trade Names: Ozex, Tomiron, Pentcillin, Tazocin, Cefoper- azin, Tomiporan, Luprac, Flucam, Baxo, Abovis, Pirocut, 03192 SIGMA PHARMACEUTICAL PLC
Indurgan, Lodine SR(TM), Mecloderm, Mecloderm F, Mep- Principal Law Firm: Fasken Martineau Stringer Saul LLP; tid(TM), Midon, Monocid*, PACIS(R), PENTASA(R), PROA- Board of Directors: Gerald Corbett (Chairman), Garry Watts MATINE(R), Reminyl(TM), Rentibloc(R), Rentylin(R), SECOND (Chief Executive Officer), Richard Adam (Non-Executive LOOK, Sertagyn, Testimonia, Trandate, Trizivir(R), VERA- Director), Ian Adamson (Managing Director, Europe and Americas), Peter Johnson (Non-Executive Director), Mark Subsidiary Companies: (100% owned unless stated): Shire Moran (Finance Director), Peter Read (Non-Executive Direc- BioChem, Inc (Canada); Shire Deutschlaand GmbH & Co KG Principal Shareholders: HBM BioVentures (Cayman) Ltd (Germany); Shire France SA (France); Shire Human Generic Management: Maria Buxton-Smith (Company Secretary), Therapies (USA); Shire Italia SpA (Italy); Shire Pharma- Paul Doherty (Head of Corporate Affairs), Jan Young (Head ceutical Contracts Ltd (Singapore); Shire Pharmaceuticals Financial Information: Consolidated figures Group Ltd; Shire Pharmaceuticals Iberica SL (Spain); Shire PRINCIPAL ACTIVITIES: Manufacture and distribution of Pharmaceuticals Ireland Ltd (Republic of Ireland); Shire US healthcare products, barrier contraceptives, footwear and Manufacturing Inc (USA); Shire, Inc (USA) Sales turnover
Mergers and Acquisitions: In Novebember 2007 the Group acquired the business and certain assets of Vasyli Australia Pty Ltd, Vasyli (NZ) Ltd, and Vasyli UK Ltd.
Major Products: Scholl footcare and footware, Durex con- Principal Shareholders: Legal & General Group plc (5.26%) doms, Regent Biogel surgical gloves, Marigold household and industrial gloves, OTC products including Syndol, Financial Information: 2006: Consolidated Figures; GAAP.
Cuprofen, Resolve, Ralgex, Tubigrip and wound manage- SOURCE BIOSCIENCE PLC
Former name: Medical Solutions plc
Trade Names: Adapta, Avanti, Cuprofen, Derbac, Diana, Dio- Address: 1 Orchard Place, Nottingham Business Park, Not- calm, Dr Scholl, Due In Uno, Durex, Durex Sensation, Eu- lactol, Fresh Step, Full Marks, Gelactiv, Hydra-Gel, Meltus, Mister Baby, Natruclear, Paramol, Party Feet, Performa, Pescura, Play, Pleasuremax, ProSport, Ralgex, Remegel, Resolve, Sauber, Scholl, Scholl Flight Socks, Syndol, Wood- Board of Directors: Laurie Turnbull (Chairman), Dr Nick Ash Subsidiary Companies: (100% owned unless stated): LIG (Managing Director), Dr Sue Foden (Non-Executive Direc- China BV (Netherlands); London International GmbH (Ger- tor), Dr Nick Leaves (Operations Director), Robin Slinger many); London International Group Ltd; London International (Non-Executive Director), Dr Thomas Weaver (Commercial Norway A/S (Norway); LRC North America Inc (USA); LRC Products Ltd; LRC Products Ticaret ve Pazarlama Ltd Sirketi PRINCIPAL ACTIVITIES: The Group is a holding company (Turkey); New Bridge Holdings BV (Netherlands); NV SSSL SIGMA PHARMACEUTICAL PLC
and the principal activities of the subsidiaries are the mar- Healthcare Belgium SA (Belgium); Qingdao London Durex Address: 1 Colonial Way, Imperial Way, Watford WD2 4LA keting and sale of microscopy hardware and software Company Limited (People’s Republic of China); Scholl Con- and image analysis and management systems, develop- sumer Products Ltd; Scholl (Investments) Ltd; Scholl Ltd; ment of intellectual property in cancer diagnosis/prognosis Scholl (UK) Ltd; Seton Schol Ireland Holdings (Republic of systems and the development, support and assembly of Ireland); Seton Scholl European Holdings BV (Netherlands); diagnostic telepathology workstations and the supply of a Seton Scholl International Ireland (Republic of Ireland); Board of Directors: B K H Shah (Chairman and Managing range of chemicals, consumables, provision of specialist Simco Ltd; Sonet Investments Ltd; Sonet Prebbles Ltd; pathology services, laboratory instruments and software Sonet Scholl Overseas Investments Ltd; Sonet Scholl UK Management: Mrs D K Shah (Manager), Mrs K Shah (Secre- for histopathology laboratories. Manufacture and supply of Ltd; SSL Americas Inc (USA); SSL Australia Pty Ltd (Aus- tary), M H Shah (Finance Director), Mrs J Shah (Manager) infection and contamination control products to the hospital tralia); SSL Canada Inc (Canada); SSL Czeska Republika Senior Executives: K H Shah (Company Secretary) and pharmaceutical industry and dermatology sro (Czech Republic); SSL Healthare Italia SpA (Italy); SSL PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals Mergers and Acquisitions: In April 2007 Source BioScience Healthcare Brands SA (Spain); SSL Healthcare Danmark Principal Banks: National Westminster Bank plc plc acquired 40% of the ordinary share capital of the private A/S (Denmark); SSL Healthcare Deutschland GmbH & Co healthcare provider Number One Health Group Limited. In KG (Germany); SSL Healthcare France SA (France); SSL July 2007 Source BioScience plc completed the acquisition Healthcare GmbH (Germany); SSL Healthcare (Hong Kong) of the entire ordinary share capital of Geneservice Limited.
Ltd (Hong Kong SAR); SSL Healthcare Hong Kong Ltd (Hong Subsidiary Companies: (100% owned unless stated): Fair- Kong SAR); SSL Healthcare Ireland Ltd (Republic of Ire- field Imaging Ltd; Fairfield Telepathology Ltd; Geneservice land); SSL Healthcare Japan Ltd (Japan); SSL Healthcare Ltd (75%); Kinetic Imaging Ltd; Medical Solutions FZ LLC SKYEPHARMA PLC
Nederland BV (Netherlands); SSL Healthcare (Norge) A/S (United Arab Emirates); Medical Solutions (London) Ltd (Norway); SSL Healthcare Oesterreich GmbH (Austria); (75%); Medical Solutions (Nottingham) Ltd (75%); Pathlore SSL Healthcare (Polska) Sp zoo (Poland); SSL Healthcare Ltd; Second Opinion Solutions AS (75.3%) (Norway) Singapore Pte Ltd (Singapore); SSL Healthcare Suisse SA Associated Companies: Number One Health Group Ltd (40%) (Switzerland); SSL Healthcare Thailand Ltd (Thailand); SSL Principal Banks: The Royal Bank of Scotland plc Hellas SA (Greece); SSL Holdings Inc (USA); SSL Mag- yarorszag Kft (Hungary); SSL Manufacturing (Thailand) Board of Directors: Jeremy Scudamore (Chairman), Frank Ltd (Thailand); SSL New Zealand Ltd (New Zealand); SSL Condella (Chief Executive Officer), Alan Bray (Non-Executive Products Ltd; SSL Romania SRL (Romania); SSL Slovnsko Director), Dr Ken Cunningham (Chief Operating Officer), Pe- spol sro (Slovakia); SSL Sverige AB (Sweden); SSL-TTK Ltd ter Grant (Finance Director), Stephen Harris (Non-Executive (51%) (India); TTK-LIG Ltd (49.87%) (India); Tubifoam Ltd Director), Dr Argeris Karabelas (Non-Executive Director), Principal Shareholders: Aberforth Partners (15.68%); Mr John Murphy (Company Secretary), Jean-Charles Tschudin S Varkey (8.65%); Mr J Mellon (5.72%); Texas Holdings PRINCIPAL ACTIVITIES: Research, development, manufacture Principal Law Firm: Allen & Overy; Hammonds Financial Information: Consolidated figures Divestments: In March 2007 the Group disposed of its In- Trade Names: Paxil CR, Xatral OD, Madopar DR, Coruno, Sales turnover
Nifedipine, Diclofenac, Dilacor XR, Requip, Statin NK-104, Principal Shareholders: Blackrock Inc (14.94%); Liontrust Foradil DPI, Formoterol HFA, Pulmicort HFA, Formoterol Investment Services Ltd (5.51%); FMR Corp (5.03%) Combi, DepoCyt, DepoMorphine, DepoBupivacaine, Psorax- ine, Interferon alpha-2b, HGH, Solareze, Hyclinda, Acyclovir, Financial Information: Consolidated figures Propofol IDD-D, Busulfan, Fenofibrate, Multiple Subsidiary Companies: (100% owned unless stated): Jago Holding AG (Switzerland); Jagotec AG (Switzerland); Sales turnover
Krypton Ltd (Gibraltar); SkePharma AG (Switzerland); SkePharma Canada Inc (Canada); SkyePharma AB (Swe- SSL INTERNATIONAL PLC
den); SkyePharma Holding AG (Switzerland); SkyePharma Address: 35 New Bridge Street, London EC4V 6BW Holding Inc (USA); SkyePharma (Jersey) Ltd; SkyePharma Production SAS (France); SkyePharma US Inc (USA) Alphabetical Index
Alphabetical
Alphabetical Index
Abbott Laboratorios Lda [Portugal ] 02605 A S Bugshan & Bros [Saudi Arabia] 00326 Index by Country
Getz Bros & Co (Singapore) Pte Ltd 01273 Said Mohamed Obaid Binzagr & Co 00352

Source: http://gale.cengage.co.uk/images/2009%20PHARMBIO%20SAMPLES.pdf

Doi:10.1016/s1474-4422(08)70020-6

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician Aaron Boster, Gilles Edan, Elliott Frohman, Adil Javed, Olaf Stuve, Alexandros Tselis, Howard Weiner, Bianca Weinstock-Guttman, Omar Khan Several lines of evidence link immunosuppression to infl ammation in patients with multiple sclerosis (MS) and Lancet Neurol 200

Microsoft word - additional_banned_list_1.doc

2013 WNBF/INBF ADDITIONAL BANNED SUBSTANCE LIST 1-Androstendiol 5α-androst-1-en-3β,17β-diol 1-AD 1-Androstendione 5α-androst-1-en-3,17-dione 1-AD 4-Androstendiol androst-4-en-3β,17β-diol Androdiol 4-Androstendione androst-4-en-3,17-dione Androsten 5-Androstendiol androst-5-en-3β,17β-diol 5-Andro 5-Androstendione androst-5-en-3,17-dione 5-Andro Bolandiol estr-4-en-3β,17β-diol Anab

Copyright © 2010-2014 Medical Articles